Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06281769Not ApplicableCompleted

Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision

Role: collaborator

NCT06974539Not ApplicableNot Yet Recruiting

TULIP ReTrain Study

Role: collaborator

NCT06935487Not ApplicableActive Not Recruiting

European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection

Role: collaborator

NCT04605276Completed

Threedimensional Multiparametric Ultrasound for Prostate Cancer Detection

Role: collaborator

All 4 trials loaded